Sign in
CompletedPhase 3

The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older.

Key facts

Who runs it
Seqirus UK Limited
Where
Denmark, Estonia, and Germany26 sites in 3 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
2,100 people enrolled
Started
3 Nov 2023
Ended
16 May 2025
Type of study
Interventional
Record updated
27 September 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Individuals, aged 50 years and older, who are healthy or have stable comorbidities that increase their risk of complications from influenza infection
  • Individuals who can comply with all study procedures

Who cannot take part

  • Influenza vaccination within 180 days prior to informed consent or plan to receive influenza vaccine within 9 months from study vaccination (all subjects) or within 12 months (subjects in the long-term subset for immunogenicity)
  • Progressive, unstable, or uncontrolled clinical conditions
  • Known hypersensitivity or allergy to any study vaccine component
  • Known history of Guillain-Barré syndrome or other demyelinating disease
  • Condition representing a contraindication to vaccination or blood draw
  • Abnormal function of immune system due to know disorder or medication

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To demonstrate in a sequential manner: First, clinical lot-to-lot consistency of 3 consecutive aQIVc HD lots, in terms of immunogenicity for each vaccine strain in subjects aged 50 years and older, as measured by hemagglutination inhibition (HI)* assay using cell-derived target viruses, at Day 29. Then, immunological noninferiority of aQIVc HD vs QIVr and vs aQIV for each vaccine strain in subjects aged 50 years and older, as measured by HI* geometric mean titers (GMTs) and seroconversion rates (SCRs), using cell-derived target viruses, at Day 29.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Older.
Record updated
27 September 2024